Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Minimal Residual Disease Eradication With Ibrutinib Therapy (MERIT) in Patients With Chronic Lymphocytic Leukemia After Frontline Therapy

NCT02649387 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT02649387
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02649387 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Minimal Residual Disease Eradication With Ibrutinib Therapy (MERIT) in Patients With Chronic Lymphocytic Leukemia After Frontline Therapy
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Completed
Start date
February 8, 2016
Completion date
January 15, 2026
Enrollment
35 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage i chronic lymphocytic leukemia, stage ii chronic lymphocytic leukemia, stage iii chronic lymphocytic leukemia, stage iv chronic lymphocytic leukemia